Contribution of vaccines to our understanding of pneumococcal disease

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 366, Issue 1579, 2011, Pages 2790-2798

  Klugman, Keith P ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Pneumococcus; Pneumonia; Vaccine

Indexed keywords

ADULT; BACTERIUM; CAUSE OF DEATH; CHILD MORTALITY; DEVELOPING WORLD; DRUG DEVELOPMENT; HOSPITAL SECTOR; INFECTIOUS DISEASE; INFLUENZA; PATHOGEN; PNEUMONIA; PROBE; PUBLIC HEALTH; TUBERCULOSIS; VACCINATION; VACCINE;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

EID: 80052429247     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2011.0032     Document Type: Review

References (65)

1. Rudan, I. et al. 2010 Causes of deaths in children younger than 5 years in China in 2008. Lancet 375, 1083-1089. (doi:10.1016/S0140-6736(10)60060-8)
2. O'Brien, K. L. et al. 2009 Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902. (doi:10. 1016/S0140-6736(09)61204-6)
3. Macleod, C. M., Hodges, R. G., Heidelberger, M. & Bernhard, W. G. 1945 Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82, 445-465. (doi:10.1084/ jem.82.6.445)
4. Avery, O. T. & Goebel, W. F. 1931 Chemo-immunological studies on carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med. 54, 419-426
5. Berkelman, R., Cassell, G., Specter, S., Hamburg, M. & Klugman, K. 2006 The 'Achilles heel' of global efforts to combat infectious diseases. Clin. Infect. Dis. 42, 1503-1504. (doi:10.1086/504494)
6. Klugman, K. P., Madhi, S. A. & Albrich, W. C. 2008 Novel approaches to the identification of Streptococcuspneumoniae as the cause of community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl. 3), S202-S206. (doi:10.1086/591405)
7. Williams, B. G., Gouws, E., Boschi-Pinto, C., Bryce, J. & Dye, C. 2002 Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis. 2, 25-32. (doi:10.1016/S1473-3099(01) 00170-0)
8. Cutts, F. T. et al. 2005 Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365, 1139-1146. (doi:10.1016/S0140-6736(05)71876-6)
9. Klugman, K. P., Madhi, S. A., Huebner, R. E., Kohberger, R., Mbelle, N. & Pierce, N. 2003 A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349, 1341-1348. (doi:10.1056/NEJMoa035060)
10. Lucero, M. G. et al. 2009 Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr. Infect. Dis. J. 28, 455-462. (doi:10.1097/INF.0b013e31819637af)
11. Madhi, S. A., Kuwanda, L., Cutland, C. & Klugman, K. P. 2005 The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and-uninfected children. Clin. Infect. Dis. 40, 1511-1518. (doi:10.1086/ 429828)
12. Madhi, S. A. & Klugman, K. P. 2007 World Health Organisation definition of 'radiologically-confirmed pneumonia' may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 25, 2413-2419. (doi:10.1016/j.vaccine.2006.09.010)
13. Grijalva, C. G., Nuorti, J. P., Arbogast, P. G., Martin, S. W., Edwards, K. M. & Griffin, M. R. 2007 Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 1179-1186. (doi:10. 1016/S0140-6736(07)60564-9)
14. Nelson, J. C., Jackson, M., Yu, O., Whitney, C. G., Bounds, L., Bittner, R., Zavitkovsky, A. & Jackson, L. A. 2008 Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 26, 4947-4954. (doi:10.1016/j.vaccine.2008.07.016)
15. De Wals, P., Robin, E., Fortin, E., Thibeault, R., Ouakki, M. & Douville-Fradet, M. 2008 Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 27, 963-968. (doi:10.1097/INF.0b013e31817cf76f)
16. Jardine, A., Menzies, R. I. & McIntyre, P. B. 2010 Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr. Infect. Dis. J. 29, 607-612. (doi:10.1097/INF. 0b013e3181d7d09c)
17. Simonsen, L., Taylor, R. J., Young-Xu, Y., Haber, M., May, L. & Klugman, K. P. 2011 Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2, e00309-e00310. (doi:10.1128/mBio.00309-10)
18. French, N. et al. 2010 A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 362, 812-822. (doi:10.1056/NEJMoa0903029)
19. Grijalva, C. G., Nuorti, J. P., Zhu, Y. & Griffin, M. R. 2010 Increasing incidence of empyema complicatingchildhood community-acquired pneumonia in the United States. Clin. Infect. Dis. 50, 805-813. (doi:10. 1086/650573)
20. Blaschke, A. J. et al. 2011 Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr. Infect. Dis. J. 30, 289-294. (doi:10.1097/INF.0b013e3182 002d14)
21. Resti, M. et al. 2010 Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin. Infect. Dis. 51, 1042-1049. (doi:10.1086/ 656579)
22. Nuorti, J. P., Butler, J. C., Farley, M. M., Harrison, L. H., McGeer, A., Kolczak, M. S. & Breiman, R. F. 2000 Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N. Engl. J. Med. 342, 681-689. (doi:10.1056/NEJM200003093421002)
23. Breiman, R. F., Keller, D. W., Phelan, M. A., Sniadack, D. H., Stephens, D. S., Rimland, D., Farley, M. M., Schuchat, A. & Reingold, A. L. 2000 Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160, 2633-2638. (doi:10.1001/archinte. 160.17.2633)
24. Feikin, D. R., Klugman, K. P., Facklam, R. R., Zell, E. R., Schuchat, A. & Whitney, C. G. 2005 Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin. Infect. Dis. 41, 481-487. (doi:10. 1086/432015)
25. Walter, N. D., Taylor Jr, T. H., Dowell, S. F., Mathis, S. & Moore, M. R. 2009 Holiday spikes in pneumococcal disease among older adults. N. Engl. J. Med. 361, 2584-2585. (doi:10.1056/NEJMc0904844)
26. Pilishvili, T. et al. 2010 Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201, 32-41. (doi:10.1086/648593)
27. Hsu, H. E. et al. 2009 Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med. 360, 244-256. (doi:10.1056/NEJMoa0800836)
28. Metersky, M. L., Dransfield, M. T. & Jackson, L. A. 2010 Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest 138, 486-490. (doi:10.1378/chest.10-0738)
29. Obaro, S. K., Adegbola, R. A., Banya, W. A. & Greenwood, B. M. 1996 Carriage of pneumococci after pneumococcal vaccination. Lancet 348, 271-272. (doi:10.1016/S0140-6736(05)65585-7)
30. Mbelle, N., Huebner, R. E., Wasas, A. D., Kimura, A., Chang, I. & Klugman, K. P. 1999 Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180, 1171-1176. (doi:10.1086/315009)
31. Cohen, A. L. et al. 2010 Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 24, 2253-2262. (doi:10.1097/QAD.0b013e32833d46fd)
32. Singleton, R. J., Hennessy, T. W., Bulkow, L. R., Hammitt, L. L., Zulz, T., Hurlburt, D. A., Butler, J. C., Rudolph, K. & Parkinson, A. 2007 Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. J. Am. Med. Assoc. 297, 1784-1792. (doi:10.1001/jama.297. 16.1784)
33. Melegaro, A., Choi, Y. H., George, R., Edmunds, W. J., Miller, E. & Gay, N. J. 2010 Dynamic models of pneumococcal carriage and the impact of the heptavalentpneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect. Dis. 10, 90. (doi:10.1186/1471-2334-10-90)
34. Gray, B. M., Converse, III, G. M. & Dillon Jr, H. C. 1980 Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J. Infect. Dis. 142, 923-933. (doi:10.1093/infdis/142.6.923)
35. Austrian, R., Douglas, R. M., Schiffman, G., Coetzee, A. M., Koornhof, H. J., Hayden-Smith, S. & Reid, R. D. 1976 Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Phys. 89, 184-194
36. O'Brien, K. L. et al. 2007 Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community- randomized trial. J. Infect. Dis. 196, 1211-1220. (doi:10.1086/521833)
37. Yang, S. et al. 2005 Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J. Clin. Microbiol. 43, 3221-3226. (doi:10.1128/JCM. 43.7.3221-3226.2005)
38. Vu, H. T. T. et al. 2011 Association between nasopharyngeal load of Streptococcus pneumoniae, viral infection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr. Infect. Dis. J. 30, 11-18. (doi:10. 1097/INF.0b013e3181f111a2)
39. Feikin, D. R. & Klugman, K. P. 2002 Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35, 547-555. (doi:10.1086/ 341896)
40. Klugman, K. P. & Friedland, I. R. 1995 Antibioticresistant pneumococci in pediatric disease. Microb. Drug Resist. 1, 5-8. (doi:10.1089/mdr.1995.1.5)
41. Kyaw, M. H. et al. 2006 Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354, 1455-1463. (doi:10.1056/NEJMoa051642)
42. Stephens, D. S. et al. 2005 Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365, 855-863. (doi:10.1016/S0140- 6736(05)71043-6)
43. Black, S., Shinefield, H., Baxter, R., Austrian, R., Elvin, L., Hansen, J., Lewis, E. & Fireman, B. 2006 Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24(Suppl. 2), S279-S280.
44. Moore, M. R. et al. 2008 Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197, 1016-1027. (doi:10.1086/528996)
45. Gertz Jr, R. E., Li, Z., Pimenta, F. C., Jackson, D., Juni, B. A., Lynfield, R., Jorgensen, J. H., Carvalho Mda, G. & Beall, B. W. 2010 Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 201, 770-775
46. van Gils, E. J. et al. 2010 Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. J. Am. Med. Assoc. 304, 1099-1106. (doi:10.1001/jama.2010.1290)
47. Madhi, S. A. & Klugman, K. P. 2004 A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10, 811-813. (doi:10.1038/nm1077)
48. Madhi, S. A., Ludewick, H., Kuwanda, L., Niekerk, N., Cutland, C., Little, T. & Klugman, K. P. 2006 Pneumococcal coinfection with humanmetapneumovirus. J. Infect. Dis. 193, 1236-1243. (doi:10.1086/503053)
49. Moore, D. P., Klugman, K. P. & Madhi, S. A. 2010 Role of Streptococcus pneumoniae in hospitalisation for acute community-acquired pneumonia associated with culture- confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr. Infect. Dis. J. 29, 1099-1104. (doi:10.1097/INF.0b013 e3181eaefff)
50. Berendt, R. F., Long, G. G. & Walker, J. S. 1975 Influenza alone and in sequence with pneumonia due to Streptococcus pneumoniae in the squirrel monkey. J. Infect. Dis. 132, 689-693. (doi:10.1093/infdis/132.6. 689)
51. McCullers, J. A. & Rehg, J. E. 2002 Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186, 341-350. (doi:10.1086/341462)
52. Sun, K. & Metzger, D. W. 2008 Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat. Med. 14, 558-564. (doi:10.1038/nm1765)
53. Shahangian, A., Chow, E. K., Tian, X., Kang, J. R., Ghaffari, A., Liu, S. Y., Belperio, J. A., Cheng, G. & Deng, J. C. 2009 Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. 119, 1910-1920. (doi:10.1172/JCI 35412)
54. McCullers, J. A., McAuley, J. L., Browall, S., Iverson, A. R., Boyd, K. L. & Henriques Normark, B. 2010 Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J. Infect. Dis. 202, 1287-1295. (doi:10.1086/656333)
55. Abdullahi, O., Nyiro, J., Lewa, P., Slack, M. & Scott, J. A. 2008 The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr. Infect. Dis. J. 27, 59-64. (doi:10.1097/INF. 0b013e31814da70c)
56. Brimblecombe, F. S., Cruickshank, R., Masters, P. L., Reid, D. D. & Stewart, G. T. 1958 Family studies of respiratory infections. Br. Med. J. 1, 119-128. (doi:10.1136/bmj.1.5063.119)
57. Gwaltney Jr, J. M., Sande, M. A., Austrian, R. & Hendley, J. O. 1975 Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J. Infect. Dis. 132, 62-68. (doi:10.1093/infdis/132.1.62)
58. Morens, D. M., Taubenberger, J. K. & Fauci, A. S. 2008 Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198, 962-970. (doi:10.1086/591708)
59. Chien, Y. W., Klugman, K. P. & Morens, D. M. 2009 Bacterial pathogens and death during the 1918 influenza pandemic. N. Engl. J. Med. 361, 2582-2583. (doi:10.1056/NEJMc0908216)
60. Chien, Y. W., Klugman, K. P. & Morens, D. M. 2010 Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J. Infect. Dis. 202, 1639-1648. (doi:10. 1086/657144)
61. Chintu, C. et al. 2002 Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 360, 985-990. (doi:10.1016/S0140-6736(02)11082-8)
62. Jeena, P. M., Pillay, P., Pillay, T. & Coovadia, H. M. 2002 Impact of HIV-1 co-infection on presentation andhospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int. J. Tuberc. Lung Dis. 6, 672-678
63. Johnson, H. L., Deloria-Knoll, M., Levine, O. S., Stoszek, S. K., Freimanis Hance, L., Reithinger, R., Muenz, L. R. & O'Brien, K. L. 2010 Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 7, e1000348. (doi:10.1371/journal.pmed.1000348)
64. Lu, Y. J. et al. 2010 Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin. Vaccine Immunol. 17, 1005-1012. (doi:10.1128/CVI. 00036-10)
65. Lu, Y. J. et al. 2010 GMP-grade pneumococcal wholecell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspirationsepsis. Vaccine 28, 7468-7475. (doi:10.1016/j.vaccine. 2010.09.031)